eHealth, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; comparative period is Q1 2023. eHealth operates an online health-insurance marketplace and enrollment platform, with Medicare and Employer and Individual (E&I) segments. Amounts below are in U.S. dollars.
Financial performance and liquidity
- Revenue: $93.0 million, up 26% year over year. Commission revenue was $80.9 million (+19%); other revenue was $12.0 million (+110%), primarily reflecting higher sponsorship revenue.
- Profitability: Operating loss was $17.9 million versus $22.9 million; net loss was $17.0 million versus $19.9 million. Net loss attributable to common stockholders was $27.7 million, or $0.96 per share, versus $28.0 million, or $1.01 per share. Operating margin improved to approximately negative 19% from negative 31%.
- Segment results: Medicare revenue rose 33% to $82.4 million, and segment profit was $8.3 million versus a $0.6 million loss. E&I revenue fell 11% to $10.6 million; segment profit declined 39% to $4.7 million.
- Cash flow: Operating cash flow was $70.8 million versus $60.8 million. The quarter’s cash generation was substantially supported by a $73.1 million decrease in commissions receivable. Investing activities used $10.3 million; financing activities used $1.3 million. Management reported positive trailing-12-month operating cash flow of $3.3 million at quarter-end.
- Liquidity: Cash, cash equivalents and short-term marketable securities totaled $188.9 million at March 31, compared with $121.7 million at December 31. Current assets were $404.4 million and current liabilities $146.0 million.
- Debt and preferred stock: The secured term loan had a carrying value of $68.2 million, a 13.10% interest rate, and a February 2025 maturity; it was classified as current. The company reported compliance with loan covenants. Series A convertible preferred stock was carried at $307.4 million and is senior to common equity; cash dividends accrue at 2% annually, alongside 6% PIK dividends.
- Receivables: Net commissions receivable totaled $845.3 million, concentrated among carriers; Humana, UnitedHealthcare and Aetna represented 28%, 26% and 16% of commissions receivable and accounts receivable, respectively.
Material changes versus Q1 2023
- Revenue growth was led by Medicare, including higher approved members and improved estimated commission lifetime value. Medicare approved members rose 10%; total approved members increased 1% to 98,259.
- Estimated total membership declined 5% to 1.18 million, including a 1% decrease in Medicare membership and declines in E&I, ancillary and small-business membership.
- Marketing and advertising expense increased 18% to $38.7 million, while customer care and enrollment expense rose 31% to $32.9 million, reflecting investment in advisors, dedicated-carrier efforts and retention.
- General and administrative expense decreased 19% to $19.6 million. Technology and content expense decreased 7% to $13.3 million.
- The quarter included $6.3 million of impairment, restructuring and other charges: $5.5 million of non-cash office-asset impairments and $0.8 million of restructuring charges.
- The company changed its facilities-expense allocation methodology. Prior-period expense categories and segment results were recast; the change did not affect total operating expenses, operating loss or net loss.
Outlook, risks and unusual items
- Management’s 2024 strategy emphasizes deliberate enrollment and revenue growth, revenue diversification, improved conversion, retention and enrollment quality, and fixed-cost reduction. It said it plans to resume E&I enrollment growth in Q4 2024. No numerical full-year guidance is provided in the supplied filing text.
- Management believes existing liquidity and expected collections will fund operations for at least 12 months after filing and support refinancing or other alternatives for the February 2025 term-loan maturity. Future financing availability and terms remain uncertain.
- The company failed its preferred-investor agreement’s 2.5x minimum asset coverage ratio at the September 2023 measurement date. This gave H.I.G. additional governance rights; a H.I.G.-designated board observer was appointed in March 2024. eHealth reported compliance with the agreement’s minimum liquidity requirement at March 31, 2024.
- Key risks include dependence on a small number of carriers, commission and membership estimates, member retention, seasonal enrollment, rising acquisition costs, competition, changing Medicare regulations, privacy and cybersecurity, and refinancing the high-rate term loan. The filing discusses CMS’s April 2024 Medicare Advantage and Part D rules and a Senate Finance Committee information request received in January 2024 concerning lead generation, marketing and enrollment.
- Two derivative actions were dismissed without prejudice in January and March 2024. The company reported no material litigation-related accruals for the quarter; it cautions that legal and regulatory matters could still result in costs or other adverse effects.
Important facts for investors to verify
- Whether Medicare enrollment growth and improved estimated commission values convert into durable cash collections and retained members.
- How the $845.3 million commissions-receivable balance performs, given reliance on carrier reporting, estimation uncertainty and carrier concentration.
- Plans and available financing to address the $68.2 million term loan maturing in February 2025, including the effect of its 13.10% rate.
- Compliance with preferred-investor liquidity and asset-coverage terms, and the implications of H.I.G.’s additional governance rights and preferred-stock redemption provisions.
- Whether E&I operational changes restore enrollment growth as management expects, and whether higher acquisition spending improves conversion, retention and profitability.
- The financial and operational impact of Medicare regulatory changes, the Senate inquiry, and any related carrier or regulatory actions.